7 results about "Urocystitis" patented technology

The invention belongs to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating radiation cystitis and a preparation method thereof. The traditional Chinese medicine composition comprises the following components: roasted rhizoma atractylodis macrocephalae, poria cocos, raw rice kernels, polyporus umbellatus, fingered citron, prepared rhizoma polygonati, pericarpium citri reticulatae, hairyvein agrimony, lalang grass rhizome, Huai wheat, lysimachia christinae hance, plantain herb and lygodium japonicum. In the formula, lysimachia christinae hance, plantain herb and lygodium japonicum have the effects of clearing heat, inducing diuresis and treating stranguria, bighead atractylodes rhizome, poria cocos, rice kernel, grifola and Huai wheat are used as auxiliary materials for tonifying spleen and promoting diuresis, hairyvein agrimony astringes to stop bleeding, lalang grass rhizome has the effects of clearing heat, inducing diuresis and stopping bleeding, prepared rhizoma polygonati has the effects of tonifying kidney essence and preparing fire with water, and all the medicines are combined to clear away the toxicity of pathogenic fire of radioactive rays on bladder meridian. The traditional Chinese medicine composition for treating radiation cystitis has the advantages of definite curative effect, few toxic and side effects and good clinical application value.

The application discloses a traditional Chinese medicine compound composition, preparation and a preparation method thereof for treating acute radiation cystitis, and belongs to the technical field of medicines. The traditional Chinese medicine compound composition for treating acute radiation cystitis is prepared based on the screening of compound components by means of modern molecular biology and the theory of traditional Chinese medicine compound, and is prepared from Lysimachia christinae 2-4 parts, Herba Epimedii 1-3 parts, Herba Patriniae 2-4 parts, Smilax glabra 2-4 parts, Sophora flavescens 0.8-2.8 parts, Lobelia 1-3 parts, Semen Lagenariae 1.4-3.4 parts, Hippophae rhamnoides 1-3 parts, Herba Erigerontis 1-3 parts and Glycyrrhiza 1-3 parts by extraction. The traditional Chinese medicine compound can solve the problems of lack of targeted mechanism intervention, limited curative effect, large side effect and poor patient compliance in the prior art; in addition, the application proposes key target points and effective components of drugs for treating acute radiation cystitis, and experiments prove that the treatment effect on acute radiation cystitis is obvious.

The invention discloses a traditional Chinese medicine compound composition for treating acute radiation cystitis, a preparation and a preparation method thereof, and belongs to the technical field of medicines. The traditional Chinese medicine compound composition for treating acute radiation cystitis is prepared by screening compound components on the basis of modern molecular biology means and combining the traditional Chinese medicine compound theory. The traditional Chinese medicine compound composition for treating acute radiation cystitis is prepared by extracting 2-4 parts of lysimachia christinae hance, 1-3 parts of herba epimedii, 2-4 parts of herba patriniae, 2-4 parts of rhizoma smilacis glabrae, 0.8-2.8 parts of radix sophorae flavescentis, 1-3 parts of Chinese lobelia, 1.4-3.4 parts of semen cuscutae, 1-3 parts of sea-buckthorn, 1-3 parts of erigeron breviscapus and 1-3 parts of liquorice. The traditional Chinese medicine compound can solve the problems of lack of targeted mechanism intervention, limited curative effect, large side effect, poor patient compliance and the like in the existing treatment; in addition, the invention provides key targets and effective components of drugs for acute radiation cystitis, and experiments prove that the pharmaceutical composition has an obvious treatment effect on acute radiation cystitis.

To provide methods and kits for identifying a companion animal having an increased risk of developing interstitial cystitis; along with compositions for treating the same.SOLUTION: A pet food composition comprises an effective amount of a fiber-bound polyphenol component, for use in increasing the level of a urinary cytokine selected from: Fms-like tyrosine kinase 3 (F1t3-L), a stem cell factor (SCF); and IL-12p40, in a companion animal.SELECTED DRAWING: Figure 1A

The invention relates to the use of epidermal growth factor for the manufacture of a medicament for the treatment of interstitial cystitis. The "epidermal growth factor" (EGF) of the invention can be used to manufacture an excellent medicament for interstitial cystitis. The medicament has a composition that includes an active ingredient, adjuvant, dispersant, wetting agent, and / or suspension agent. The carrier of the epidermal growth factor is water, colloid, hyaluronic acid, natural oils, and / or glucose. The medicament serves to reduce urinary frequency. The medicament serves to restore bladder elasticity. The medicament serves to reduce cystitis. The medicament serves to increase the antioxidant capacity in bladder tissue.The present invention proposes a novel effect of epidermal growth factor, which can be used to treat interstitial cystitis and to repair the bladder mucosa and exhibits excellent efficacy.

The present disclosure provides a method for treating interstitial cystitis / bladder pain syndrome in a human subject in need of such treatment, comprising administering a therapeutically effective amount of a compound of formula (I) or its pharma- ceutical acceptable salt to the human subject.In certain embodiments, the method comprises administering a compound of formula (IA).

The invention belongs to the technical field of exosome application, and discloses a triptolide-loaded nano co-delivery drug delivery carrier and application thereof in preparation of drugs for treating interstitial cystitis. The triptolide-loaded nano co-delivery drug delivery carrier is used for interstitial cystitis model animals, and the following changes are observed: 1, the sensitivity of the model animals to stimulation is reduced; 2, the urination frequency of model animals is reduced, and the urination volume of words is increased; 3, the number of red blood cells in urine of the model animal is reduced; 4, bladder tissue hyperemia is relieved, and the size is reduced; and 5, the expression of inflammatory factors IL-6, MCP-1, ICAM-1 and BAX is obviously reduced. Therefore, it can be determined that the triptolide-loaded nano-co-delivery drug delivery carrier is used for treating interstitial cystitis. According to the research, the application range of the triptolide is expanded, and the triptolide is combined with the exosome to be used for treating the interstitial cystitis, so that a new thought is provided for treating the interstitial cystitis.